Skip to main content
Equibles
CNMD logo

CNMD · CONMED Corp · Metrics

Track CNMD — free

Use CNMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$44.29 -1.43 (-3.13%) At close · Oct 30 Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.32B
Shares
29.80M
Volume · Oct 30 404.1K Avg daily vol (3M) 385.17K

CNMD metrics

104 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$44.29
Market cap
$1.32B

Price action

20 metrics
Price change (1W)
-10.1%
Price change (30D)
-3.6%
Price change (3M)
-4.3%
Price change (6M)
+20.4%
Price change (YTD)
+9.1%
Price change (1Y)
-0.4%
Trailing year
Price change (5Y)
-69.7%
52-week high
$51.86
52-week low
$32.11
Change from 52-week high
-14.6%
Change from 52-week low
+37.9%
Annualized volatility
44.8%
Annualized volatility (3M)
40.0%
Beta
0.7
RSI (14D)
40.6
Price vs SMA 50
-5.9%
Price vs SMA 200
+7.0%
Avg volume (3M)
385,172
Relative volume
1.1
Average dollar volume
$18.35M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
29.80M

Valuation

12 metrics
P / E (TTM)
18.3
Trailing earnings · reciprocal yield 5.5%
PEG ratio
0.0
EV / revenue
1.5×
reciprocal yield 65.6%
EV / EBITDA
—
EV / EBIT
15.4×
reciprocal yield 6.5%
P / sales
1.0×
reciprocal yield 103.7%
P / book
1.2
reciprocal yield 80.3%
FCF yield
10.1%
TTM · current market cap
Buyback yield
—
P / FCF
9.9
reciprocal yield 10.1%
P / operating cash flow
9.0
reciprocal yield 11.1%
Earnings yield
5.6%

Historical valuation

8 metrics
P / E historical average (3Y)
21.4×
reciprocal yield 4.7%
P / E historical average (5Y)
28.8×
reciprocal yield 3.5%
EV / revenue historical average (3Y)
1.9×
reciprocal yield 51.5%
EV / revenue historical average (5Y)
2.7×
reciprocal yield 36.4%
EV / EBIT historical average (3Y)
17.9×
reciprocal yield 5.6%
EV / EBIT historical average (5Y)
31.6×
reciprocal yield 3.2%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
8.4%
Shareholder yield
0.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
0
Last ex-dividend
2025-09-15

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-28

Profitability

9 metrics
Gross margin
57.6%
Operating margin
9.9%
Trailing 12 months
Net margin
5.4%
Gross profit (TTM)
$788.34M
Operating profit (TTM)
$135.59M
Net income (TTM)
$73.43M
Trailing 12 months
Diluted EPS (TTM)
$2.42
FCF margin
9.7%
Effective tax rate
30.0%

Per share

11 metrics
Revenue per diluted share (TTM)
$44.81
Gross profit per diluted share (TTM)
$25.79
Operating profit per diluted share (TTM)
$4.44
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$2.41
Operating cash flow per diluted share (TTM)
$4.79
Free cash flow per diluted share (TTM)
$4.35
Capital expenditures per diluted share (TTM)
$0.44
R&D per diluted share (TTM)
$2.04
Stock compensation per diluted share (TTM)
$0.71
Book value per share
—

Growth

11 metrics
Revenue growth YoY
-0.7%
Year over year
Net income growth YoY
+592.4%
Revenue (TTM)
$1.37B
Trailing 12 months
EPS growth YoY
+633.3%
Shares change YoY
-3.0%
Year over year · fewer shares
Revenue CAGR (3Y)
+9.6%
Revenue CAGR (5Y)
+9.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
+36.4%
FCF CAGR (3Y)
+135.3%
FCF CAGR (5Y)
+24.0%

Quality

14 metrics
Return on equity
6.9%
Return on assets
3.2%
Debt / equity
0.8
Current ratio
1.5
EBITDA (TTM)
—
Free cash flow (TTM)
$132.69M
Quick ratio
0.7
Interest coverage
4.1
Net debt / EBITDA
—
Return on invested capital
5.2%
Trailing 12 months
Net cash
−$767.89M
Latest balance sheet
Cash & equivalents
$47.97M
Total assets
$2.30B
Total debt
$815.87M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$146.31M
Capital expenditures (TTM)
$13.62M
R&D (TTM)
$62.32M
SG&A (TTM)
$590.43M
Stock compensation (TTM)
$21.61M
R&D / revenue
4.6%
Stock compensation / revenue
1.6%

Ownership (13F)

9 metrics
13F filers
248
13F filer change QoQ
+9
Institutional ownership
114.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-0.3%
Holder tenure
14.0
Price vs estimated holder cost
-45.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
32.3%

Short interest

3 metrics
Short interest
6.4%
Latest settlement · 4.7 days to cover
Days to cover
4.7d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 816956 CUSIP 207410101 13F (30d) 86 filings 68 filers Visit website Investor relations